Huang, Ruyi
Nikooyan, Ali A.
Moore, Lisa D.
Zdunowski, Sharon
Morikawa, Erika
Sierro, Tiffany
Sayenko, Dimitry
Gad, Parag
Homsey, Tali
Le, Timothy
Madhavan, Meghna A.
Abdelshahid, Marina
Abdelshahid, Martina
Zhou, Yan
Nuwer, Mark R.
Sarrafzadeh, Majid
Edgerton, V. Reggie
Leiter, James C.
Lu, Daniel C.
Funding for this research was provided by:
J. Yang & Family Foundation
National Institutes of Health (EB15521, EB15521, EB15521, EB15521, EB15521, EB15521, EB15521, EB15521, EB15521)
Foundation for the National Institutes of Health (UL1TR000124, UL1TR000124, UL1TR000124, UL1TR000124, UL1TR000124, UL1TR000124, UL1TR000124, UL1TR000124, UL1TR000124)
Article History
Received: 8 December 2021
Accepted: 14 April 2022
First Online: 11 May 2022
Competing interests
: D.C.L has shareholder interest in Onward and Restore Technologies. V.R.E. has shareholder interest in Onward and SpineX. PG has shareholder interest in SpineX. After ending affiliation with UCLA, L.M. gained employment at Boston Scientific Corporation and later became a stakeholder in Boston Scientific Corporation. The content of this publication is under the sole responsibility of its author/publisher and does not represent the views or opinions of Boston Scientific Corporation. All the other authors have no competing-interest (R.H., A.A.N., S.Z., E.M., T.S., D.S., T.L., T.H., M.M., M.A., M.A., Y.Z., M.R.N., M.S., and J.C.L.).